Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
2021-01-07 23:49IvanRosas
四川生理科学杂志 2021年2期
Ivan O Rosas
Conclusions:In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F.Hoffmann-La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number,NCT04320615.).
- 四川生理科学杂志的其它文章
- Auto-aggressive CXCR6 + CD8 T cells cause liver immune pathology in NASH
- The molecular assembly of the marsupial γμ T cell receptor defines a third T cell lineage
- Liver type 1 innate lymphoid cells develop locally via an interferon-γ-dependent loop
- Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
- Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults
- The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia